Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode

By sjmartinez • December 11, 2024

Pollack CV Jr, Arroyo D, Kanda E, Lázaro IJS, Lesén E, Franzén S, Gray CM, Lipińska A, Murohara T, Rastogi A. Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode. ESC Heart Fail. 2024 Dec 10. doi: 10.1002/ehf2.15171. Epub ahead of print. PMID: 39659133.

Tags: Chronic kidney disease, heart failure, hyperkalaemia, Nephrology, Potassium binder, Publications, renin–angiotensin–aldosterone system inhibitor, sodium zirconium cyclosilicate

Advancing Equitable Kidney Care through Population Health Approaches in Los Angeles County’s Safety Net System

Kalantar-Zadeh K, Raff EA, Chong CC, Yang JK, Le TK, Barba LM, Pham PC, Dhamija R, Ghaffari A, Khine A, Patel N, Nicholas SB, Sim[...]

Prevalence and Outcomes of Chronic Kidney Disease-Associated Pruritus: International Results from Peritoneal Dialysis Outcomes and Practice Patterns Study

Tennankore KK, McCullough K, Bieber B, Cho Y, Johnson DW, Kanjanabuch T, Kawanishi H, Kim YL, Lambie M, Rigatto C, Shen J, Schreiber M, Perl[...]

Disparities in Care: Desperate for Modality Education

Shen JI, Perl J. Disparities in Care: Desperate for Modality Education. J Am Soc Nephrol. 2024 Dec 3. doi: 10.1681/ASN.0000000578. Epub ahead of print. PMID:[...]